Ipsen

Equities

IPN

FR0010259150

Pharmaceuticals

Market Closed - Euronext Paris 12:35:52 2024-03-28 pm EDT 5-day change 1st Jan Change
110.3 EUR +1.01% Intraday chart for Ipsen +3.37% +2.22%

This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan MT
IPSEN : Ipsen’s underlying fundamentals remain promising Alphavalue
Deutsche Bank Reduces Ipsen PT, Keeps Hold Rating MT
IPSEN : Deutsche Bank cuts its target CF
IPSEN : UBS reiterates its buy recommendation CF
Merrimack Pharmaceuticals to Receive $225 Million Milestone Payment From Ipsen MT
Ipsen: new indication approved in pancreatic cancer CF
US FDA OKs Ipsen's Metastatic Pancreatic Adenocarcinoma Treatment Regimen in Adults MT
Merrimack Pharmaceuticals to Get $225 Million Milestone Payment After FDA's Supplemental NDA Approval DJ
Ipsen?s Onivyde Regimen, Potential New Standard-Of-Care First-Line Therapy in Metastatic Pancreatic Adenocarcinoma, Approved by FDA CI
Ipsen S.A. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
IPSEN : In line Q4 sales; lower-than-expected 2024 guidance Alphavalue
Transcript : Ipsen S.A., 2023 Earnings Call, Feb 08, 2024
Ipsen: 13% drop in annual EPS CF
Transcript : Ipsen S.A., 2023 Pre Recorded Earnings Call, Feb 08, 2024
Ipsen presents positive data for Cabometyx CF
Ipsen Announces Latest Phase III Trial Data Investigating Cabometyx®? in Combination with Immunotherapy to Be Present at ASCO Gu 2024 CI
IPSEN : Deutsche Bank lowers its target price CF
IPSEN : Ipsen outlined some promising mid-term takeaways at the CMD Alphavalue
IPSEN : UBS remains Buy after CMD CF
Genfit: upbeat after updated outlook CF
Transcript : Ipsen S.A. - Analyst/Investor Day
Ipsen, Genfit's Liver Disease Drug Gains Regulatory Submission Acceptances in US, Europe, UK MT
Ipsen Confirms U.S. FDA Grants Priority Review for New Drug Application for Elafibranor for the Treatment of Rare, Cholestatic Liver Disease, PBC CI
Genfit: filing for elafibranor accepted by the FDA CF
Chart Ipsen
More charts
Ipsen specialises in the research, development, manufacture and marketing of specialty medicines. Net sales by therapeutic area break down as follows: - oncology (75.2%); - neuroscience (21.1%); - rare diseases (3.7%). At the end of 2023, the group had 4 research and development centres located in France, the United Kingdom, the United States and China, and 4 manufacturing sites worldwide. Net sales are distributed geographically as follows: Europe (40.2%), North America (33.3%) and other (26.5%).
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
B+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
15
Last Close Price
110.3 EUR
Average target price
124.8 EUR
Spread / Average Target
+13.17%
Consensus
  1. Stock
  2. Equities
  3. Stock Ipsen - Euronext Paris
  4. News Ipsen
  5. Ipsen : Exicure to Develop Treatment for Neurodegenerative Illnesses